A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2018
At a glance
- Drugs Cediranib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2018 Status changed from active, no longer recruiting to completed.
- 30 Aug 2013 Planned end date changed from 1 Mar 2007 to 1 Jun 2010 as reported by ClinicalTrials.gov.